These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15035028)

  • 1. Clostridia in cancer therapy.
    Minton NP
    Nat Rev Microbiol; 2003 Dec; 1(3):237-42. PubMed ID: 15035028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
    Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM
    Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic tumour targeting using clostridial spores.
    Minton NP; Mauchline ML; Lemmon MJ; Brehm JK; Fox M; Michael NP; Giaccia A; Brown JM
    FEMS Microbiol Rev; 1995 Oct; 17(3):357-64. PubMed ID: 7576773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
    Fox ME; Lemmon MJ; Mauchline ML; Davis TO; Giaccia AJ; Minton NP; Brown JM
    Gene Ther; 1996 Feb; 3(2):173-8. PubMed ID: 8867865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
    Liu SC; Minton NP; Giaccia AJ; Brown JM
    Gene Ther; 2002 Feb; 9(4):291-6. PubMed ID: 11896468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters.
    Nuyts S; Theys J; Landuyt W; van Mellaert L; Lambin P; Anné J
    Anticancer Res; 2001; 21(2A):857-61. PubMed ID: 11396175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy.
    Kubiak AM; Minton NP
    Res Microbiol; 2015 May; 166(4):244-54. PubMed ID: 25576776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
    Benouchan M; Do Nascimento F; Perret GY; Colombo BM
    Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.
    Theys J; Pennington O; Dubois L; Anlezark G; Vaughan T; Mengesha A; Landuyt W; Anné J; Burke PJ; Dûrre P; Wouters BG; Minton NP; Lambin P
    Br J Cancer; 2006 Nov; 95(9):1212-9. PubMed ID: 17024128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment.
    Barbé S; Van Mellaert L; Theys J; Geukens N; Lammertyn E; Lambin P; Anné J
    FEMS Microbiol Lett; 2005 May; 246(1):67-73. PubMed ID: 15869963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of beta-lactamase-dependent prodrugs in clostridial-directed enzyme therapy (CDEPT): a proposal.
    Tirandaz H; Hamedi J; Marashi SA
    Med Hypotheses; 2006; 67(4):998-9. PubMed ID: 16797858
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacterial targeted tumour therapy-dawn of a new era.
    Wei MQ; Mengesha A; Good D; Anné J
    Cancer Lett; 2008 Jan; 259(1):16-27. PubMed ID: 18063294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining gene and immunotherapy for prostate cancer.
    Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
    Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery to tumours: recent strategies.
    Reddy LH
    J Pharm Pharmacol; 2005 Oct; 57(10):1231-42. PubMed ID: 16259751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
    Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour-Clostridium phenomenon: 50 years of developmental research (Review).
    Schmidt W; Fabricius EM; Schneeweiss U
    Int J Oncol; 2006 Dec; 29(6):1479-92. PubMed ID: 17088987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of clostridial spores for cancer treatment.
    Barbé S; Van Mellaert L; Anné J
    J Appl Microbiol; 2006 Sep; 101(3):571-8. PubMed ID: 16907807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of bacteria in anti-cancer therapies.
    Ryan RM; Green J; Lewis CE
    Bioessays; 2006 Jan; 28(1):84-94. PubMed ID: 16369949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.
    Heap JT; Theys J; Ehsaan M; Kubiak AM; Dubois L; Paesmans K; Van Mellaert L; Knox R; Kuehne SA; Lambin P; Minton NP
    Oncotarget; 2014 Apr; 5(7):1761-9. PubMed ID: 24732092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clostridium spores as anti-tumour agents.
    Van Mellaert L; Barbé S; Anné J
    Trends Microbiol; 2006 Apr; 14(4):190-6. PubMed ID: 16500103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.